GlycoFi, Inc. and Biogen, Inc. (NASDAQ: BGEN) announce the initiation of a joint research study to evaluate GlycoFi’s Humanized yeastä platform for the production of an undisclosed Biogen protein. The study, supported by Biogen, will combine GlycoFi’s unique expression technology to produce human glycoproteins of unprecedented uniformity with Biogen’s expertise in the area of therapeutic protein discovery and manufacturing.
GlycoFi, Inc. is the industry leader for the engineering and production of therapeutic glycoproteins in yeast systems. The company was founded in 2000 with the mission to be a leading biotechnology company in the development, manufacturing, and commercialization of biotherapeutics. The company has engineered yeast and other fungal protein expression systems to produce fully humanized glycoproteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information, please visit www.glycofi.com.
Biogen is the world’s oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients’ lives around the world through its global marketing capabilities. For press releases and additional information about the company, please visit www.biogen.com.